A San Diego-based biotechnology company that pioneered muscle-targeted RNA delivery through its proprietary Antibody Oligonucleotide Conjugate platform, Avidity Biosciences was acquired by Novartis in February 2026 for approximately $12 billion.
A San Diego-based biotechnology company that pioneered muscle-targeted RNA delivery through its proprietary Antibody Oligonucleotide Conjugate platform, Avidity Biosciences was acquired by Novartis in February 2026 for approximately $12 billion.
